Publications by authors named "Justine Lam"

Claim this Profile
E
Exposure-Response Analysis of Repotrectinib to Support the Dose Recommendation for Patients With ROS1-Positive NSCLC or NTRK-Positive Solid Tumors.
Shengnan Du, Zheyi Hu, Jun Shen, Li Zhu, Amit Roy, Justine Lam

CPT Pharmacometrics Syst Pharmacol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Empirical Autoinduction Model to Characterize the Population Pharmacokinetics and Recommend Dose for Repotrectinib in Adult and Adolescents With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements.
Shengnan Du, Zheyi Hu, Jun Shen, Lora Hamuro, Justine Lam

CPT Pharmacometrics Syst Pharmacol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response Regarding: Digital Ink and Surgical Dreams: Perceptions of Artificial Intelligence-Generated Essays in Residency Applications.
Loralai M Crawford, Justine Lam, Lisa M Cannon, Yanjie Qi, Lauren DeCaporale-Ryan

J Surg Res· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Digital Ink and Surgical Dreams: Perceptions of Artificial Intelligence-Generated Essays in Residency Applications.
Loralai M Crawford, Peter Hendzlik, Justine Lam, Lisa M Cannon, Yanjie Qi

J Surg Res· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolism, Excretion, and Pharmacokinetics of Lorlatinib (PF-06463922) and Evaluation of the Impact of Radiolabel Position and Other Factors on Comparability of Data Across 2 ADME Studies.
Daria Stypinski, Luke Fostvedt, Justine L Lam, Alfin Vaz, Theodore R Johnson

J Clin Pharmacol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolism, excretion and pharmacokinetics of [C]glasdegib (PF-04449913) in healthy volunteers following oral administration.
Justine L Lam, Alfin Vaz, Brian Hee, Yali Liang, Xin Yang

Xenobiotica· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematologic malignancies.
Shu-Hui Liu, Yin Gu, Bernadette Pascual, Zhengming Yan, Max Hallin, Justine Lam

Blood Adv· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.
Helen Y Zou, Luc Friboulet, David P Kodack, Lars D Engstrom, Qiuhua Li, Hieu Lam, Justine L Lam

Cancer Cell· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
Helen Y Zou, Qiuhua Li, Lars D Engstrom, Melissa West, Vicky Appleman, Justine Lam

Proc Natl Acad Sci U S A· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanistic understanding of translational pharmacokinetic-pharmacodynamic relationships in nonclinical tumor models: a case study of orally available novel inhibitors of anaplastic lymphoma kinase.
Shinji Yamazaki, Justine L Lam, Helen Y Zou, Hui Wang, Tod Smeal

Drug Metab Dispos· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1.
Shinji Yamazaki, Justine L Lam, Helen Y Zou, Hui Wang, Tod Smeal

J Pharmacol Exp Ther· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.
Ted W Johnson, Paul F Richardson, Simon Bailey, Alexei Brooun, Benjamin J Burke, Hieu Lam, Justine L Lam

J Med Chem· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib.
Qinhua Huang, Ted W Johnson, Simon Bailey, Alexei Brooun, Kevin D Bunker, Hieu Lam, Justine L Lam

J Med Chem· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pan-FGFR inhibition leads to blockade of FGF23 signaling, soft tissue mineralization, and cardiovascular dysfunction.
Gina M Yanochko, Allison Vitsky, Jonathan R Heyen, Brad Hirakawa, Justine L Lam

Toxicol Sci· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin.
Manthena V S Varma, Jian Lin, Yi-An Bi, Charles J Rotter, Odette A Fahmi, Justine L Lam

Drug Metab Dispos· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effective targeting of Hedgehog signaling in a medulloblastoma model with PF-5274857, a potent and selective Smoothened antagonist that penetrates the blood-brain barrier.
Allison Rohner, Mary E Spilker, Justine L Lam, Bernadette Pascual, Darian Bartkowski

Mol Cancer Ther· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression and functional analysis of hepatic cytochromes P450, nuclear receptors, and membrane transporters in 10- and 25-week-old db/db mice.
Justine L Lam, Ying Jiang, Tao Zhang, Eric Y Zhang, Bill J Smith

Drug Metab Dispos· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elucidating the effect of final-day dosing of rifampin in induction studies on hepatic drug disposition and metabolism.
Justine L Lam, Sarah B Shugarts, Hideaki Okochi, Leslie Z Benet

J Pharmacol Exp Ther· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporter-enzyme interplay.
Justine L Lam, Hideaki Okochi, Yong Huang, Leslie Z Benet

Drug Metab Dispos· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes.
Justine L Lam, Leslie Z Benet

Drug Metab Dispos· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis